-+ 0.00%
-+ 0.00%
-+ 0.00%

OPUS GENETICS ANNOUNCES FIRST PARTICIPANT DOSED IN PHASE 1/2 CLINICAL TRIAL OF OPGX-RDH12 GENE THERAPY FOR RARE INHERITED CHILDHOOD BLINDNESS

Reuters·11/19/2026 12:00:01

Please log in to view news